| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2002 | 2652 | 2002 |
| 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus A Fanouriakis, M Kostopoulou, A Alunno, M Aringer, I Bajema, JN Boletis, ... Annals of the rheumatic diseases 78 (6), 736-745, 2019 | 1995 | 2019 |
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ... Medicine 82 (5), 299-308, 2003 | 1847 | 2003 |
| Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients R Cervera, MA Khamashta, J Font, GD SEBASTIANI, A Gil, P Lavilla, ... Medicine 72 (2), 113-124, 1993 | 1387 | 1993 |
| Immunosuppressive therapy in lupus nephritis: the Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide FA Houssiau, C Vasconcelos, D D'Cruz, GD Sebastiani, ER Garrido, ... Arthritis & Rheumatism 46 (8), 2121-2131, 2002 | 1352 | 2002 |
| Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of … GK Bertsias, M Tektonidou, Z Amoura, M Aringer, I Bajema, JHM Berden, ... Annals of the rheumatic diseases 71 (11), 1771-1782, 2012 | 1270 | 2012 |
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients R Cervera, R Serrano, GJ Pons-Estel, L Ceberio-Hualde, Y Shoenfeld, ... Annals of the rheumatic diseases 74 (6), 1011-1018, 2015 | 1171* | 2015 |
| Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides FA Houssiau, JP Devogelaer, JV Damme, CND Deuxchaisnes, JV Snick Arthritis & Rheumatism: Official Journal of the American College of …, 1988 | 1121 | 1988 |
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including … GK Bertsias, JPA Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, ... Annals of the rheumatic diseases 67 (2), 195-205, 2008 | 1055 | 2008 |
| Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 B Klein, XG Zhang, M Jourdan, J Content, F Houssiau, L Aarden, ... | 1015 | 1989 |
| Treat-to-target in systemic lupus erythematosus: recommendations from an international task force RF Van Vollenhoven, M Mosca, G Bertsias, D Isenberg, A Kuhn, ... Annals of the rheumatic diseases 73 (6), 958-967, 2014 | 856 | 2014 |
| Two-year, randomized, controlled trial of belimumab in lupus nephritis R Furie, BH Rovin, F Houssiau, A Malvar, YKO Teng, G Contreras, ... New England Journal of Medicine 383 (12), 1117-1128, 2020 | 808 | 2020 |
| 2019 update of the joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the … A Fanouriakis, M Kostopoulou, K Cheema, HJ Anders, M Aringer, ... Annals of the rheumatic diseases 79 (6), 713-723, 2020 | 799 | 2020 |
| The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide FA Houssiau, C Vasconcelos, D D’Cruz, GD Sebastiani, ... Annals of the rheumatic diseases 69 (01), 61-64, 2010 | 616 | 2010 |
| Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ... Medicine 78 (3), 167-175, 1999 | 604 | 1999 |
| Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial FA Houssiau, D D'Cruz, S Sangle, P Remy, C Vasconcelos, R Petrovic, ... Annals of the rheumatic diseases 69 (12), 2083-2089, 2010 | 594 | 2010 |
| Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long‐term followup of patients in the Euro‐Lupus Nephritis Trial FA Houssiau, C Vasconcelos, D D'Cruz, GD Sebastiani, ... Arthritis & rheumatism 50 (12), 3934-3940, 2004 | 481 | 2004 |
| Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus TRDJ Radstake, O Gorlova, B Rueda, JE Martin, BZ Alizadeh, ... Nature genetics 42 (5), 426-429, 2010 | 468 | 2010 |
| Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo … DJ Wallace, K Kalunian, MA Petri, V Strand, FA Houssiau, M Pike, ... Annals of the rheumatic diseases 73 (1), 183-190, 2014 | 410 | 2014 |
| A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) R Van Vollenhoven, A Voskuyl, G Bertsias, C Aranow, M Aringer, ... Annals of the rheumatic diseases 76 (3), 554-561, 2017 | 403 | 2017 |
